U.S. Online Retail and Ecommerce Stock News

XCF Global (SAFX) has drawn fresh attention after a series of updates, including a Q1 2026 operational briefing, a business combination agreement, a forbearance deal with lender Twain, and a sector conference appearance. See our latest analysis for XCF Global. Recent updates around the Reno facility restart, the business combination agreement, and the Twain forbearance deal have coincided with a sharp shift in sentiment, with a 90 day share price return of 166.1% but a 3 year total...

The market for SuperCom Ltd.'s ( NASDAQ:SPCB ) stock was strong after it released a healthy earnings report last week...

Readers hoping to buy Lazard, Inc. ( NYSE:LAZ ) for its dividend will need to make their move shortly, as the stock is...

Dave Inc. has already reported first-quarter 2026 results, with revenue rising to US$158.41 million and net income to US$57.94 million, driving basic earnings per share from continuing operations to US$4.31. Beyond the headline growth, the company beat analyst earnings expectations for a fourth consecutive quarter and raised its 2026 guidance, underscoring management’s confidence and the traction of new products like its Pay in 4 card test. We’ll now examine how Dave’s raised 2026 guidance...

United Therapeutics Corporation has already reported first-quarter 2026 results, with sales of US$781.5 million and net income of US$274.9 million, both lower than the same period last year and below analyst expectations. The earnings shortfall contrasts with earlier optimism driven by positive ralinepag Phase 3 data and pipeline milestones in pulmonary disease and organ technologies, sharpening investor focus on how reliably current products can fund future innovation. Against this backdrop...

In April 2026, Guardant Health announced a multi-year collaboration with Nuvalent to use its Guardant Infinity platform’s tissue and liquid biopsy tests in supporting Nuvalent’s global oncology trials and potential commercialization efforts. This alliance highlights how pairing Nuvalent’s kinase-targeted cancer therapies with Guardant’s precision diagnostics could tighten patient selection, streamline regulatory pathways, and strengthen future companion diagnostic strategies. Next, we’ll...

Q1 2026 earnings snapshot sets up margins story for Travere Therapeutics (TVTX) Travere Therapeutics (TVTX) heads into its Q1 2026 update with recent quarterly revenue of US$129.7 million in Q4 2025 and basic EPS of US$0.29 in Q3 2025 giving way to a loss of US$0.24 per share in Q4, alongside trailing 12 month revenue of US$490.7 million and a net loss of US$50.3 million. Over the past year, revenue has moved from US$233.2 million on a trailing 12 month basis in Q4 2024 to US$490.7 million in...

Spectrum Brands Holdings (NYSE:SPB) has entered into a partnership with Oaktree Capital Management focused on its Home and Personal Care business. The transaction brings new investment into the segment and marks another step in Spectrum Brands' plan to separate this business from the rest of the company. The move is intended to reshape how Spectrum Brands allocates resources across its portfolio and could influence how investors view the stock. At a share price of $82.38 and with a return...

In late April 2026, PROG Holdings reported first-quarter 2026 results showing revenue of US$742.67 million and net income of US$36.05 million, alongside higher earnings per share from continuing operations compared with a year earlier. The company also raised its full-year 2026 guidance for revenues and earnings from continuing operations, underscoring management’s confidence in its ongoing business transformation beyond Progressive Leasing, including Four Technologies and other newer...

Amcor (NYSE:AMCR) has entered exclusive talks to sell its ESE World waste management unit. The company has also agreed to sell two North American beverage closure plants. Together, these asset moves point to a reshaping of Amcor’s portfolio toward its core packaging operations. For investors watching NYSE:AMCR, these portfolio changes arrive after a stretch of weaker share performance, with the stock down 10.5% year to date and 13.1% over the past year, at a recent price of $37.64. In that...

We wouldn't blame Viavi Solutions Inc. ( NASDAQ:VIAV ) shareholders if they were a little worried about the fact that...

Why Galaxy Digital’s latest earnings matter for investors Galaxy Digital (GLXY) moved into focus after first quarter earnings showed sales and revenue ahead of analyst expectations, a narrower loss, and a stock reaction closely tied to Bitcoin’s surge and improving macro sentiment. See our latest analysis for Galaxy Digital. The recent rally in Galaxy Digital’s stock, with a 71.88% 1 month share price return and a 61.28% 1 year total shareholder return, points to building momentum as...

Diamond Hill Capital has initiated a new position in Knowles (NYSE:KN), citing confidence in the reshaped portfolio and growth potential. The move highlights fresh institutional interest in the company beyond recent earnings, guidance and valuation discussions. Knowles shares last closed at $33.28, with the stock up 9.7% over the past week and 106.1% over the past year. For investors watching Knowles, Diamond Hill Capital’s new stake puts a spotlight on how the company’s portfolio reset is...

Amphenol (NYSE:APH) has launched a dual tranche Eurobond offering totaling more than €1.1b. The Euro denominated senior notes are intended to refinance existing US borrowings and fund general corporate purposes. This is Amphenol’s first large scale debt capital market transaction announced in 2026. For investors watching Amphenol at a share price of $136.69, this Eurobond move adds an important piece to the picture. The stock has gained 72.7% over the past year and 331.6% over five years,...

Chiesi Farmaceutici S.p.A. has entered into a definitive agreement to acquire KalVista Pharmaceuticals (NasdaqGM:KALV). The deal includes a tender offer followed by a merger process, with completion subject to specified closing conditions. Responsibility for EKTERLY®, a treatment for hereditary angioedema (HAE), is set to move from KalVista to Chiesi once the transaction is finalized. KalVista focuses on treatments for hereditary angioedema, and EKTERLY® is a key product in that portfolio...

Wondering if V.F at around US$18.32 is still offering value after a volatile few years, or if the easy gains are already behind it. The stock is up 53.5% over the last year, alongside a 0.9% year to date return, an 8.6% gain over 30 days and a 2.1% decline over the last week. This suggests shifting views on both its recovery potential and risk. Recent headlines around V.F have focused on the company reshaping its portfolio and responding to changing consumer demand. Investors are closely...

Wondering whether Meta Platforms at around US$604.96 is still a compelling stock or if most of the value is already on the table? This article breaks down what the current price may be implying. The stock has seen a 9.9% decline over the last 7 days, a 5.3% gain over the last 30 days, a 7.0% decline year to date, and a 3.3% return over the last year, with longer term returns of 161.3% over 3 years and 98.9% over 5 years. Recent headlines have focused on Meta Platforms' long term share price...

Evaluating whether Ares Management is attractively priced at the moment, or if the stock already reflects its potential, begins with understanding how its current market value compares with its fundamentals. The stock recently closed at US$122.96, with a 7 day return of 8.8%, a 30 day return of 20.0%, a year to date return showing a 26.1% decline, a 1 year return showing a 20.4% decline, a 3 year return of 66.9%, and a 5 year return of 173.5%. Recent headlines around Ares Management have...

In recent days, Vanguard Capital Management disclosed a 5.07% passive ownership stake in Astronics, coinciding with more favorable analyst sentiment and upward revisions to earnings estimates. This combination of a new institutional holder and shifting views on Astronics’ earnings power has sharpened debate over whether the company’s current valuation fully reflects its prospects. We’ll now examine how Vanguard’s newly reported passive stake could influence Astronics’ existing investment...

Leostream Corporation and Nutanix (NasdaqGS:NTNX) have partnered to deliver unified remote access solutions for high performance computing environments. The collaboration brings together Nutanix infrastructure with Leostream's access platform to support scalable GPU workloads across cloud and hybrid cloud deployments. The new offering focuses on certified integrations and deeper interoperability for enterprises running distributed, compute intensive applications. Nutanix focuses on hybrid...

For investors wondering whether Figma at around US$19.42 is starting to look like value or still carries more downside risk, this article breaks down what the current price implies. Figma’s stock has moved 13.0% over the last 7 days, but is still down 8.7% over 30 days and 48.4% year to date. This raises questions about how the market is reassessing its potential and risks. Recent coverage around Figma has focused on its role in design software and the broader interest in software platforms...

Recent performance snapshot for DNOW (DNOW) DNOW (DNOW) has drawn attention after a solid month, with the stock up about 12.7% while the past 3 months show a roughly 15.2% decline, leaving year to date returns near 1.9%. See our latest analysis for DNOW. That recent 12.7% 1 month share price return contrasts with a 1 year total shareholder return of about a 15.1% decline, hinting that short term momentum is improving after a weaker stretch. If you are weighing DNOW against other opportunities...

Coca-Cola FEMSA. de: recent performance snapshot Coca-Cola FEMSA. de (KOF) has drawn investor interest after recent trading, with the stock last closing at US$106.58 and showing positive returns over the past week, month, and year. See our latest analysis for Coca-Cola FEMSA. de. The recent 5.3% 1 day share price return and 7.9% 30 day share price return sit alongside a 17.4% 1 year total shareholder return and 165.4% 5 year total shareholder return. This suggests that momentum has been...

Why Wyndham Hotels & Resorts Stock Is On Watch Wyndham Hotels & Resorts (WH) has delivered mixed return patterns, with the stock up about 7% over the past 3 months yet showing a small decline over the past year, which may prompt closer investor attention. See our latest analysis for Wyndham Hotels & Resorts. The recent pullback, including a 7 day share price return of a 5.9% decline and a 30 day share price return of a 2.2% decline, contrasts with a 6.8% gain over 3 months and a 26.5% three...